0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Synovics Pharmaceuticals
Its shares trade under the ticker SYVC. It has been listed since 19 December 1994. In the fiscal year to 31 October 2008, it reported revenue of $26.0m and a net loss of $4.0m. At that date it held total assets of $22.3m and shareholders' equity of $5.0m.
Synovics Pharmaceuticals, Inc. engages in the manufacture and sale of pharmaceutical and dietary supplement products. The company is headquartered in Fort Lauderdale, Florida. The firm is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The firm has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Dec 1994
- Employees
- 155
Leadership
Pay as last reported
- Mr. Ronald LaneChairman of the Board, Secretary, since 1994$353,846
- Jyotindra GangeInterim Principal Executive Officer, Director, since 2008
- Mahendra DesaiChief Financial Officer$10,384
- John CopanosVP - Business Development of Kirk Pharmaceuticals LLC$232,932
- Maneesh SapteDirector
- Vinay SapteDirector
- Harcharan SinghDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Synovics Pharmaceuticals Inc possesses several key strengths that contribute to its success in the pharmaceutical industry. Firstly, it has a strong portfolio of patented drugs and intellectual property rights, which provides a competitive advantage and ensures revenue generation. Additionally, the company has a highly experienced and skilled research and development team, enabling the development of innovative and effective drugs. Moreover, Synovics Pharmaceuticals Inc maintains strong partnerships with leading healthcare institutions and key opinion leaders, fostering collaboration and ensuring the company stays at the forefront of medical advancements.
- Furthermore, Synovics Pharmaceuticals Inc has a robust manufacturing and distribution network, allowing for efficient and timely delivery of its products to healthcare providers and patients. The company's strong brand image and reputation for quality and reliability also contribute to its competitive position in the market.
Weaknesses
- Despite its strengths, Synovics Pharmaceuticals Inc has some inherent weaknesses that pose challenges to its operations. One such weakness is the company's heavy reliance on a limited number of drugs for a significant portion of its revenue. This concentration exposes the company to potential risks associated with patent expirations, generic competition, and changes in market dynamics. Additionally, Synovics Pharmaceuticals Inc may face difficulties in obtaining regulatory approvals for its new drugs or navigating complex regulatory landscapes in different countries, which can impact the company's ability to expand its market reach.
- Another weakness is the company's relatively small size compared to some of its competitors. This limits Synovics Pharmaceuticals Inc's financial resources and may hinder its ability to invest in extensive marketing and sales activities, potentially affecting its market share and growth opportunities.
Opportunities
- Synovics Pharmaceuticals Inc can capitalize on various opportunities to enhance its performance and market position. Firstly, the increasing global demand for innovative pharmaceutical products and treatments presents a significant opportunity for the company to expand its product portfolio and penetrate new markets. Furthermore, advancements in technology and data analytics can enable Synovics Pharmaceuticals Inc to develop personalized medicine and targeted therapies, catering to individual patient needs and preferences.
- Additionally, strategic collaborations with research institutions and biotechnology companies can offer access to novel drug candidates and cutting-edge research, fueling the company's pipeline and competitive advantage. Synovics Pharmaceuticals Inc can also explore strategic partnerships with local distributors and manufacturers in emerging markets, allowing for cost-effective production and distribution, as well as establishing a presence in untapped regions.
Threats
- Synovics Pharmaceuticals Inc faces various threats that can potentially impact its business operations and market performance. Firstly, the competitive landscape in the pharmaceutical industry is intense, with the presence of established multinational corporations and generic drug manufacturers. This competition can hinder market share growth and put downward pressure on product pricing and profitability.
- Moreover, regulatory frameworks and government policies related to drug pricing, intellectual property, and clinical trials can create uncertainties and additional challenges for Synovics Pharmaceuticals Inc. Changes in healthcare reforms, reimbursement policies, or the introduction of new regulations may impact the company's ability to commercialize its products effectively.
- Additionally, the emergence of disruptive technologies and alternative treatments, such as gene therapies or biologics, may pose a threat to Synovics Pharmaceuticals Inc's traditional pharmaceutical offerings. Market trends towards cost-effective generic drugs or the increasing preference for natural remedies can also impact the demand for the company's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.